CORT125134

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Jun 1, 2016 → Sep 1, 2018

NCT ID

NCT02804750

About CORT125134

CORT125134 is a phase 2 stage product being developed by Corcept Therapeutics for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02804750. Target conditions include Cushing's Syndrome.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Syndrome were approved

Approved (2) Terminated (1) Active (7)

✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved

✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved

🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3

🔄Pasireotide sub-cutaneousNovartisPhase 3

🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3

🔄PasireotideNovartisPhase 3

🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02804750	Phase 2	Completed	Jun 1, 2016	Sep 1, 2018	Cushing's Syndrome
NCT06094712	Phase 1	Completed	Apr 7, 2016	Apr 27, 2016	Healthy

Competing Products

18 competing products in Cushing's Syndrome

See all competitors

Product	Company	Stage	Hype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone	AstraZeneca	Phase 2	35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg	Novartis	Phase 3	40
Pasireotide sub-cutaneous	Novartis	Phase 3	40
osilodrostat + osilodrostat Placebo	Novartis	Phase 3	40
Osilodrostat	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 3	40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin	Novartis	Approved	43
SOM230 s.c.	Novartis	Phase 2	35
Lu AG13909	Lundbeck	Phase 2	39
Osilodrostat	Recordati	Pre-clinical	23
Pasireotide + Cabergoline + Pasireotide LAR	Recordati	Approved	40
osilodrostat	Recordati	Phase 2	32
Osilodrostat	Recordati	Pre-clinical	27
mifepristone	Corcept Therapeutics	Phase 3	37
Cushing's syndrome confirmation	Corcept Therapeutics	Pre-clinical	15
Mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	29